Valuation: Sanofi

Market Cap 94.34B 110B 88.28B 80.7B 152B 10,508B 154B 1,041B 406B 5,298B 414B 404B 17,537B P/E 2026 *
12.6x
P/E 2027 * 11x
Enterprise Value 106B 124B 99B 90.5B 171B 11,784B 172B 1,168B 455B 5,942B 464B 454B 19,666B EV / Sales 2026 *
2.22x
EV / Sales 2027 * 2.02x
Free-Float
88.34%
Yield 2026 *
5.4%
Yield 2027 * 5.71%
1 week+1.55%
Current month+5.35%
1 month+3.68%
3 months+1.55%
6 months-1.99%
Current year-3.43%
1 week 38.4
Extreme 38.4
39.4
1 month 36.2
Extreme 36.2
40
3 years 35.6
Extreme 35.6
55
5 years 35.6
Extreme 35.6
55
10 years 30.6
Extreme 30.6
55
Manager TitleAgeSince
Chief Executive Officer 65 30/04/2026
Director of Finance/CFO 64 31/03/2024
Chief Tech/Sci/R&D Officer 51 10/09/2023
Director TitleAgeSince
Director/Board Member 60 29/04/2019
Director/Board Member 57 27/04/2020
Director/Board Member 65 27/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.51%+2.62%-8.80%-19.59% 109B
-1.06%+4.27%+73.34%+125.12% 1,111B
+0.53%+4.10%+52.35%+65.45% 658B
+0.48%+6.18%+26.21%+81.27% 467B
+0.92%+4.97%+42.94%+43.69% 369B
+1.25%+4.00%+25.87%+42.82% 301B
+3.02%+7.92%+4.24%+16.06% 256B
-0.36%+5.45%+50.57%+72.33% 240B
+2.86%+5.27%-15.42%-52.34% 207B
+1.38%+7.09%+29.62%+94.90% 182B
Average +1.21%+4.49%+28.09%+46.97% 421.22B
Weighted average by Cap. +1.09%+4.68%+42.63%+70.47%

Financials

2026 *2027 *
Net sales 47.59B 55.57B 44.54B 40.71B 76.87B 5,301B 77.55B 525B 205B 2,673B 209B 204B 8,847B 50.7B 59.19B 47.44B 43.37B 81.89B 5,647B 82.61B 559B 218B 2,847B 222B 217B 9,424B
Net income 7.91B 9.24B 7.4B 6.77B 12.78B 881B 12.89B 87.3B 34.02B 444B 34.68B 33.92B 1,471B 9.24B 10.79B 8.65B 7.91B 14.93B 1,030B 15.06B 102B 39.75B 519B 40.52B 39.63B 1,718B
Net Debt 11.46B 13.38B 10.72B 9.8B 18.51B 1,276B 18.67B 126B 49.26B 643B 50.23B 49.12B 2,130B 8.3B 9.69B 7.77B 7.1B 13.41B 925B 13.53B 91.64B 35.71B 466B 36.4B 35.6B 1,544B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Date Price Change
25/08/26 €39.40 +0.51%
24/08/26 €39.20 0.00%
21/08/26 €39.20 +1.55%
20/08/26 €38.60 -1.03%
19/08/26 €39.00 +0.52%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
78.74EUR
Average target price
94.28EUR
Spread / Average Target
+19.73%

Quarterly revenue - Rate of surprise